share_log

Grail | 10-Q: Quarterly report

Grail | 10-Q: Quarterly report

Grail | 10-Q：季度報表
美股SEC公告 ·  2024/08/13 17:03

Moomoo AI 已提取核心訊息

GRAIL reported Q2 2024 revenue of $32.0 million, up 43% year-over-year, driven by increased Galleri test volume. Screening revenue grew 41% to $28.2 million while development services revenue increased 59% to $3.8 million. The company recorded a net loss of $1.6 billion, primarily due to a $1.4 billion goodwill and intangible asset impairment charge.Following a portfolio review, GRAIL announced a restructuring plan to focus on its core multi-cancer early detection business and reduce costs. The plan includes a 30% reduction in workforce and planned hires, affecting approximately 350 current employees. The company expects annual cost savings of $120 million and projects the restructuring will extend its cash runway from 2026 into 2028.As of June 30, 2024, GRAIL had $958.8 million in cash and cash equivalents, bolstered by $932.3 million in disposal funding received from Illumina in connection with the spin-off completed on June 24, 2024. The company has sold over 215,000 commercial Galleri tests to date and established more than 140 commercial partnerships with healthcare systems, employers, payors and life insurance providers.
GRAIL reported Q2 2024 revenue of $32.0 million, up 43% year-over-year, driven by increased Galleri test volume. Screening revenue grew 41% to $28.2 million while development services revenue increased 59% to $3.8 million. The company recorded a net loss of $1.6 billion, primarily due to a $1.4 billion goodwill and intangible asset impairment charge.Following a portfolio review, GRAIL announced a restructuring plan to focus on its core multi-cancer early detection business and reduce costs. The plan includes a 30% reduction in workforce and planned hires, affecting approximately 350 current employees. The company expects annual cost savings of $120 million and projects the restructuring will extend its cash runway from 2026 into 2028.As of June 30, 2024, GRAIL had $958.8 million in cash and cash equivalents, bolstered by $932.3 million in disposal funding received from Illumina in connection with the spin-off completed on June 24, 2024. The company has sold over 215,000 commercial Galleri tests to date and established more than 140 commercial partnerships with healthcare systems, employers, payors and life insurance providers.
GRAIL報告2024年第二季度營業收入爲3200萬美元，同比增長43%，這得益於Galleri測試成交量的增加。篩查營業收入增長了41%，達到2820萬美元，而開發服務營業收入增加了59%，達到380萬美元。公司記錄的淨虧損爲16億，主要由於14億美元的商譽和無形資產減值費用。經過投資組合審查，GRAIL宣佈了一項重組計劃，以專注於其核心的多癌種早期檢測業務並降低成本。該計劃包括將勞動力和計劃招聘減少30%，影響約350名現有員工。公司預計每年可節省12000萬美元的成本，並預計重組將把其現金儲備從2026年延長到2028年。截至2024年6月30日，GRAIL的現金及現金等價物爲95880萬美元，因收到來自Illumina的93230萬美元處置資金而加強，這與2024年6月24日完成的分拆相關。公司迄今已售出超過215,000個商業Galleri測試，並與醫療系統、僱主、支付方和人壽保險提供者建立了140多個商業合作伙伴關係。
GRAIL報告2024年第二季度營業收入爲3200萬美元，同比增長43%，這得益於Galleri測試成交量的增加。篩查營業收入增長了41%，達到2820萬美元，而開發服務營業收入增加了59%，達到380萬美元。公司記錄的淨虧損爲16億，主要由於14億美元的商譽和無形資產減值費用。經過投資組合審查，GRAIL宣佈了一項重組計劃，以專注於其核心的多癌種早期檢測業務並降低成本。該計劃包括將勞動力和計劃招聘減少30%，影響約350名現有員工。公司預計每年可節省12000萬美元的成本，並預計重組將把其現金儲備從2026年延長到2028年。截至2024年6月30日，GRAIL的現金及現金等價物爲95880萬美元，因收到來自Illumina的93230萬美元處置資金而加強，這與2024年6月24日完成的分拆相關。公司迄今已售出超過215,000個商業Galleri測試，並與醫療系統、僱主、支付方和人壽保險提供者建立了140多個商業合作伙伴關係。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    23andMe
    ME
    -- 0.770
    XWELL Inc
    XWEL
    -- 1.1900
    紐爾真檢測
    NEOG
    -- 8.960
    Aspira Women's Health
    AWH
    -- 0.1100
    Personalis
    PSNL
    -- 3.580
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點